Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 4/20 | 0.60 |
| ▸ | RHOA | P61586 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15402203 | 0.86 | KCNH3 (0.61) | KCNH3NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL12432784 | 0.86 | RHOA (0.69) | KCNH3RHOANPC1RAB9AMEN1 | |
| SCHEMBL15402542 | 0.82 | KCNH3 (0.59) | KCNH3KMT2A | |
| SCHEMBL15403837 | 0.81 | KCNH3 (0.57) | KCNH3KMT2A | |
| SCHEMBL6330053 | 0.80 | HDAC11 (0.58) | HTTHDAC11HDAC8NR1H4 | |
| SCHEMBL21940532 | 0.80 | HDAC11 (0.58) | HTTHDAC11HDAC8NR1H4 | |
| SCHEMBL6330083 | 0.80 | HDAC11 (0.58) | HTTHDAC11HDAC8NR1H4 | |
| SCHEMBL30012465 | 0.80 | HDAC11 (0.58) | HTTHDAC11HDAC8NR1H4 | |
| SCHEMBL6332453 | 0.80 | HDAC11 (0.58) | HTTHDAC11HDAC8NR1H4 | |
| SCHEMBL15403203 | 0.80 | KCNH3 (0.59) | KCNH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346768-B2 | Molecular glasses with functionalizable groups | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENSE (CA) | 2016-05-24 | — | — | US | disclosed |
| US-9328076-B2 | Molecular glasses with functionalizable groups | HER MAJESTY IN THE RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF DEFENSE (CA) | 2016-05-03 | — | — | US | disclosed |
| US-20150232433-A1 | Molecular Glasses With Functionalizable Groups | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2015-08-20 | — | — | US | disclosed |
| US-20140005370-A1 | MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005370-A1 | MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS | GNG2, GDI1, F12 | KCNH3 172/4885RHOA 51/4885NPC1 3325/4885 |
| US-20150232433-A1 | Molecular Glasses With Functionalizable Groups | GDI1, GNG2, F12 | KCNH3 202/4885RHOA 43/4885NPC1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.